SAN DIEGO, April 19, 2016 /PRNewswire/ -- ALSP, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims directed to a group of ALP-496-related compounds, which ALSP had earlier licensed from Columbia University.
Michael Pierschbacher, PhD, CEO, stated, “This issuance significantly increases the depth of our patent-approved pipeline of potential drug candidates.”
About ALSP, Inc.
ALSP, Inc. is a privately held company in San Diego, California, developing small molecule drugs for treating neurodegenerative diseases, initially focused on TBI and Alzheimer’s Disease (AD).
Further information: www.alspinc.com
Forward-Looking Statements:
This release contains “forward-looking statements” as defined under U.S. federal securities laws.
For More Information Contact:
Michael D Pierschbacher, CEO
MPierschbacher@alspinc.com
619-922-3600
Leslie V Barrett, Investor Relations
lesliebarrett@gmail.com
415-531-4618
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/american-life-science-pharmaceuticals-inc-alsp-inc-obtains-patent-300253437.html
SOURCE American Life Science Pharmaceuticals, Inc.
